Highlights

  • Second quarter revenue fell 4.5% to $678.2 million, with organic revenue down 4.9% on lower pass through costs.
  • GAAP operating income was $14.8 million versus a $330.3 million loss a year earlier, which included $309.1 million of impairments.
  • The net loss narrowed to $13.2 million, or $0.14 per share, and backlog was $7.8 billion at June 30, 2026.
  • Thermo Fisher and Clario sued over the CFO appointment, and a July 25 order bars the executive from working there.

Fortrea (NASDAQ:FTRE) shares were trading near their 52-week high at USD 23.78 on October 21, 2026, up 4.39%. The contract research organization filed its second quarter 2026 report on July 29, which disclosed a July court action over its chief financial officer appointment and an interim CFO named effective July 27.

Based in Durham, North Carolina, Fortrea is a Delaware corporation, incorporated on January 31, 2023, and separated from Labcorp on June 30, 2023. It describes itself as a global contract research organization serving pharmaceutical, biotechnology and medical device customers, with phase I to IV clinical trial management, clinical pharmacology and consulting services under Full Service, Functional Service Provider (FSP) and Hybrid models. It has one reportable segment, about 14,000 employees and operations in about 100 countries. Its fiscal year ends December 31.

Lower Revenue, Wider Operating Profit and a Smaller Loss

Revenue for the three months ended June 30, 2026 was $678.2 million, down from $710.3 million. Organic revenue declined 4.9%, with lower pass through costs and weaker demand for the FSP business partly offset by growth in clinical pharmacology, and currency added 0.4%. For six months, revenue was $1,314.7 million, down 3.4%.

Direct costs fell 6.6% to $539.0 million, or 79.5% of revenue versus 81.2%. Selling, general and administrative expenses dropped 18.2% to $102.1 million, helped by restructuring actions and lower credit loss provisions. Segment operating income rose to $39.9 million from $25.4 million, and restructuring and other charges eased to $2.7 million from $10.3 million.

GAAP operating income was $14.8 million, against an operating loss of $330.3 million in the prior-year quarter, which carried $309.1 million of goodwill and other asset impairments tied to the Clinical Development reporting unit. Interest expense declined to $19.3 million. Income tax expense rose to $12.0 million despite a pre-tax loss of $1.2 million, leaving a net loss of $13.2 million, or $0.14 per share, versus $374.9 million, or $4.14.

CFO Litigation, Securities Suit and Balance Sheet

On July 6, 2026, Thermo Fisher Scientific, Clario Holdings and eResearch Technology filed an action in the Delaware Court of Chancery against Jason Knoblauch and Fortrea over his appointment as chief financial officer. The plaintiffs allege his employment violates restrictive covenants and that he kept confidential information. On July 25, the court entered a temporary restraining order barring him from performing services for Fortrea pending further order. The company disagrees with the allegations, is complying and intends to defend. Board member David R. Smith became interim CFO on July 27. A hearing on a preliminary injunction was expected to be scheduled for early September, and the filing does not report an outcome.

The filing also describes a purported securities class action in the Southern District of New York, where a motion to dismiss is pending. The company says it has valid defenses but cannot estimate a possible loss.

Cash and cash equivalents were $168.6 million at June 30, 2026. Operating cash flow was $11.9 million for the six months, against $102.4 million used a year earlier. Long-term debt, less current portion, was $1,037.2 million, including $494.3 million of 7.5% senior notes due 2030, with $17.1 million current. The $450 million revolver was undrawn. It extended its $300 million receivables facility to February 2029. Management believes liquidity covers at least 12 months.

Backlog and What the Filing Signals Ahead

Backlog was $7.8 billion at June 30, 2026. Remaining performance obligations were about $4,442.5 million, with roughly 26% expected as revenue over the next 12 months. The company cautions that backlog is not a consistent indicator of future revenue.

The 10-Q gives no numerical revenue or earnings guidance. It says restructuring actions under plans approved in the fourth quarters of 2024 and 2025 are expected to continue through 2026.